drugset / Trial / NCT03126110
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
Timeline
- Start
- 2017-04-25
- Primary completion
- 2021-11-09
- Completion
- 2021-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | RAGIFILIMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | RAGIFILIMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | RAGIFILIMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | RAGIFILIMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | RAGIFILIMAB | Monoclonal antibody | 300 mg | Intravenous |